A Long-term Follow up Study of EXG102-031 in Participants With wAMD

Recruiting now

Conditions studied: Wet Age-related Macular Degeneration

In brief

This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.

Key facts

Study ID

NCT06859515

Run by

Guangzhou Jiayin Biotech Ltd

People needed

42

Starts

2025-03-13

Expected to finish

2030-12-01

Last updated by the study team

2025-08-15

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously received treatment with EXG102-031 in the study (EXG102-031-111);
• Paticipantes are informed consent and willingness to follow protocol procedures.

You may not qualify if…

• Paticipantes are unwilling or unable to participate in long-term follow-up

Where it is running

• Peking University People's Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.